LOS ANGELES–(BUSINESS WIRE)–Forcyte Biotechnologies, a tech-enabled drug discovery company targeting diseases of mechanobiology, has secured new funding from Milestone View,
Forcyte has been awarded a $1.5M phase 2 SBIR to continue developing functional assays for cellular contractility to support programs
The collaborative App Note can be requested directly from Molecular Devices. Inquiries may be directed to info@forcytebio.com. Free assay samples
Forcyte has been selected as 1 of 8 companies given a presentation space at the Society of Laboratory Automation and
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute
